Pretax income is the income that a company earns before paying income taxes. Marizyme's pretax income for the
three
months ended in Mar. 2024 was $-6.23 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-69.02 Mil.
Marizyme's pretax margin was -18,866.67%.
During the past 13 years, Marizyme's highest Pretax Margin was -300.00%. The lowest was -16380.26%. And the median was -2592.33%.
Marizyme Pre-Tax Income Historical Data
The historical data trend for Marizyme's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Marizyme's Pre-Tax Income
For the Biotechnology subindustry, Marizyme's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marizyme's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marizyme's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Marizyme's Pre-Tax Income falls into.
Marizyme Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Marizyme's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marizyme (OTCPK:MRZM) Pre-Tax Income Explanation
Marizyme's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, Marizyme's highest Pretax Margin was -300.00%. The lowest was -16380.26%. And the median was -2592.33%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marizyme Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Marizyme's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRZM has been successfully added to your 